C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 110 filers reported holding C4 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $81,427 | -22.3% | 25,932 | +45.9% | 0.00% | – |
| Q4 2022 | $104,843 | -31.5% | 17,770 | +1.6% | 0.00% | – |
| Q3 2022 | $153,000 | +10.1% | 17,489 | -5.1% | 0.00% | – |
| Q2 2022 | $139,000 | -78.7% | 18,428 | -31.7% | 0.00% | – |
| Q1 2022 | $654,000 | -63.8% | 26,990 | -51.8% | 0.00% | -100.0% |
| Q4 2021 | $1,805,000 | +67.1% | 56,040 | +131.7% | 0.00% | 0.0% |
| Q3 2021 | $1,080,000 | +30.4% | 24,186 | +10.6% | 0.00% | – |
| Q2 2021 | $828,000 | +210.1% | 21,859 | +203.0% | 0.00% | – |
| Q1 2021 | $267,000 | +2.7% | 7,214 | -8.2% | 0.00% | – |
| Q4 2020 | $260,000 | – | 7,862 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |